R Nogueiras, C Veyrat-Durebex, PM Suchanek, M … - Diabetes, 2008 - Am Diabetes Assoc OBJECTIVE—Blockade of the CB1 receptor is one of the promising strategies for the treatment
of obesity. Although antagonists suppress food intake and reduce body weight, the role of central
versus peripheral CB1 activation on weight loss and related metabolic parameters ... Cited by 11 - Related articles - All 5 versions
- ►nih.gov G Kunos, D Osei-Hyiaman, S Bátkai, KA Sharkey, A … - Trends in pharmacological …, 2009 - Elsevier Endocannabinoids, endogenous lipid ligands of cannabinoid receptors, mediate a variety of
effects similar to those of marijuana. Cannabinoid CB 1 receptors are highly abundant in the
brain and mediate psychotropic effects, which limits their value as a potential therapeutic ... Cited by 12 - Related articles - All 7 versions
FJ Pavón, A Serrano, V Pérez-Valero, N … - Journal of …, 2008 - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ... Cited by 11 - Related articles - BL Direct - All 4 versions
RZ Chen, A Frassetto, JZ Lao, RRC Huang, JC … - European Journal of …, 2008 - Elsevier LH-21 (5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole) was previously reported
as a neutral antagonist at the cannabinoid CB 1 receptor which, despite its reported poor ability
to penetrate into the brain, suppressed food intake and body weight in rats by ... Cited by 6 - Related articles - All 4 versions
I Esposito, MC Proto, P Gazzerro, C Laezza, C Miele, … - Molecular Pharmacology, 2008 - ASPET The endocannabinoid system regulates food intake, energy, and glucose metabolism at both
central and peripheral levels. We have investigated the mechanism by which it may control glucose
uptake in skeletal muscle cells. Detectable levels of the cannabinoid receptor type 1 ... Cited by 7 - Related articles - All 5 versions
[CITATION] Non-Brain-Penetrant CB1 Receptor Antagonists as a Novel Treatment of Obesity …
D Jones - Nature reviews. Drug discovery, 2008 - ncbi.nlm.nih.gov 1: Nat Rev Drug Discov. 2008 Dec;7(12):961-2. End of the line for cannabinoid
receptor 1 as an anti-obesity target? Jones D. A wave of terminations of development
programmes for cannabinoid receptor 1 blockers for obesity ... Cited by 17 - Related articles - All 2 versions
ANA Verty, AM Allen, BJ Oldfield - Obesity, 2008 - nature.com The cannabinoid CB1 receptor antagonist rimonabant (SR 141716) produces a sustained decrease
in body weight on a background of a transient reduction in food intake. An increase in energy
expenditure has been implicated, possibly mediated via peripheral endocannabinoid ... Cited by 3 - Related articles - All 3 versions
